



Universal Biosensors

Universal Biosensors, Inc.

ARBN 121 559 993

Investor Presentation

March 2010



Important Disclaimer

- This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person.
- Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes.
- Under applicable United States securities laws all of the shares of our common stock are “restricted securities” as that term is defined in Rule 144 under the Securities Act of 1933, as amended (**Securities Act**). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.
- The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations.
- The Company is subject to a number of risks. For a summary of key risks, refer to the Company’s most recent Form 10-K filed with the United States Securities and Exchange Commission.



Investment summary


- Growth company with history of execution
- Technology newly validated with first product launch with Johnson and Johnson company, LifeScan
- This first business has strong earnings potential
- Major opportunity to “repeat the cycle” with technology extension now very well progressed
- The timing of our technology extension coincides with corporate interest
- Business development effort to establish new partnerships is underway




Universal Biosensors

Company poised for further growth

UBI.ASX: 1.65



MktVol: 0



A significant milestone – first product sales

- LifeScan's OneTouch® Verio® for diabetics launched in The Netherlands



- A new standard of accuracy in consumer blood glucose monitoring anticipates the changing regulatory environment

- Fast test time, small sample, quick, visible fill

- Marketed as “The most accurate no-coding system for monitoring blood glucose on the market”!

(www.lifescan.nl)





Roll out will continue, capacity is in place

- LifeScan and LifeScan customers pleased with strong product attributes
- UBI expects new launches into other Europe/USA in 2010-2011 – LifeScan controls timing
- New meters will permit more sophisticated segmentation
- More capacity comes on line mid-2011 at LifeScan Inverness



Universal Biosensors

Transformational manufacturing




Modern plant at Rowville, east of Melbourne

~5,000m²

75 employees

- Near term capacity approaches 2 billion strips per annum (3 lines, multiple product capability)

Power of the manufacturing



Rolls of partially completed sensors

~1 million sensors



Megatrends force market changes

Ageing population

- Additional ~500m people expected to be aged over 60 in next 20 years
 - Increase in demand for healthcare
 - Soaring healthcare costs as % of GDP

Increased incidence of chronic disease

- +80% of people over 60 in the US have at least one chronic disease. 50% have at least 2 chronic diseases and 20% have diabetes
- Major chronic diseases include:
 - Diabetes, Cardiovascular disease, COPD, Cancer, Arthritis
 - Chronic disease best managed by patients or in the community

Technology gap



- Healthcare delivery predominantly through hospitals is expensive and bottle necked
- Chronic disease requires serial measurements
- Major GP/patient tools have not changed since the 1980's

SOMETHING HAS TO CHANGE!



UBI has positioned itself to be in the right place at the right time

- Start with breakthrough technology applied to blood glucose
- Expand and apply to existing biomarkers
- Simplicity UP rather than complexity DOWN






Unique technology – validated, now extend

✓	Easy to use
✓	Quantitative
✓	Timely
✓	Low cost
✓	Flexible

- Derived from a methodology successfully used over 16bn times a year (blood glucose strip)
 - Insert strip and read
 - Small finger stick sample
- Accurate and Precise
 - Compares with lab based tests
- Results produced quickly
 - Tests expected to produce results in a matter of minutes
- Simple design and automated manufacturing process dramatically reduces costs
 - UBI can be the low cost producer
- Platform can be adapted to develop tools for many other biomarkers
- Attractive as:
 - Part of companion diagnostics for Pharma
 - Timely intervention in a diagnostic setting






Platform foundation – the glucose strip






How it works






Information rich test transient enables new possibilities




Next stage – the immunoassay strip






How the strip works





Flexible platform creates many opportunities





Universal Biosensors

The point of care search is on - corporate response to opportunity is now mainstream



- *“Roche is a pioneer in personalised healthcare: we aim to fit treatments as closely as possible to patients’ needs — to make healthcare better, safer and more cost-effective.”*
- *“Our Pharmaceuticals and Diagnostics Divisions have unparalleled expertise in molecular biology. Both divisions have industry-leading intellectual property and technology bases in this field, which they continue to strengthen through internal development and acquisitions.”*



- *Strategy: To empower individuals with the freedom to gain greater control over their own health*
- *We “focus on areas for which near-patient diagnosis and monitoring can profoundly change therapy decisions, improve outcomes and lower costs.”*



- *We are redefining the diagnosis and treatment of patients across a range of health care settings. Our goal is to take health care to patients, wherever they are located.*
- *Abbott Point of Care is headquartered in Princeton, New Jersey, with more than 1500 global employees and a presence in 84 countries*



- *“Personalized Healthcare QIAGEN leading in emerging paradigm in Healthcare”*
- *“POC technology acquired through ESE, biohelix and HDA technologies acquisitions”*



- *“ We believe that the trend among healthcare providers to adopt POC testing continues to increase, and demographic changes, reimbursement policies, a shortage of skilled laboratory workers and the availability of clinically valuable tests will increase growth in this diagnostic category*
- *More and more employers, health plans and payers are recognizing that POC testing is a cost-effective means for improving the quality of care and patient satisfaction”*



Investment summary

- Growth company with history of execution
- Technology newly validated with first product launch with Johnson and Johnson company, LifeScan
- This first business has strong earnings potential
- Major opportunity to “repeat the cycle” with technology extension now very well progressed
- The timing of our technology extension coincides with corporate interest
- Business development effort to establish new partnerships is underway



Capital structure

Summary

Number of Shares on issue	157,292,745
Market capitalization at 17 March 2010	~A\$252 million
Number of Options on issue	9,952,576
Cash (at 31 December 2009)	~A\$31.3 million